MaaT Pharma, SA
About MaaT Pharma, SA
MaaT Pharma (Microbiota as a Therapy) is a French biotech start-up, created at the end of 2014, to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis. Funded jointly by a team which brings together world-class medical-scientific and entrepreneurial skills, MaaT Pharma has the ambition of becoming a leader in microbiome protection and the treatment of dysbiosis.YEAR FOUNDED:
2014
LEADERSHIP:
Co-Founder and CEO: Herve´ Affagard
Co-Founder and Non Executive President of the Board: Dr Pierre Belichard
Co-Founder: Mr. Joël Doré
Co-Founder: Mr. Pierre Rimbaud
CAREER:
Please click here for Auspherix's job opportunities.
PIPELINE:
Please click here for MaaT Pharma's pipeline.
42 articles with MaaT Pharma, SA
-
MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013
12/1/2021
MaaT Pharma announced today that it will comment clinical data scheduled to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting and provide a corporate update for shareholders and the broader financial community during a dedicated webcast on Monday, December 13th, 2021 at 12:00 pm EST / 6:00 pm CET).
-
MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
11/9/2021
MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
-
MaaT Pharma Awarded France Relance Government Grant to Accelerate Development in Immuno-Oncology and Support Manufacturing of Next Generation Microbiome Therapies
7/20/2021
MaaT Pharma, a French clinical-stage biotech company specialized in the development of microbiome-based therapies aiming to restore the microbiome/immune system symbiosis in oncology patients, announced that its MEPA program was awarded a EURO 1.9 million grant from the Plan France Relance.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
MaaT Pharma Announces DSMB Approval to Proceed to Cohort 4 out of 5 in Phase 1b CIMON Trial Testing Capsule Formulation of Microbiome Ecosystem Therapy
6/28/2021
MaaT Pharma, a clinical-stage biotechnology company focused on developing Microbiome Ecosystem Therapies in oncology, announced that the Data Safety and Monitoring Board recommended to proceed to the fourth cohort of the dose-finding Phase 1b CIMON clinical trial, without modifications.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
MaaT Pharma Announces Publication of Results from Completed Phase 1/2 ODYSSEE Clinical Trial in Nature Communications
5/25/2021
MaaT Pharma announced that final results from its Phase 1/2 ODYSSEE clinical trial have been published in the journal, Nature Communications.
-
MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease
3/17/2021
MaaT Pharma announced positive topline results from its Phase 2 clinical trial evaluating lead microbiome ecosystem therapy, MaaT013, in a high-risk patient population with grade III-IV steroid-refractory, gastrointestinal-predominant acute graft-versus-host disease.
-
MaaT Pharma to Provide Clinical Data for Lead Microbiome Ecosystem Therapeutic MaaT013 in Intestinal Acute GvHD at Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
3/11/2021
Data from 29 patients in the company’s early access program with MaaT013 as a treatment for gastrointestinal acute Graft-versus-Host Disease will be highlighted in an oral presentation
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
MaaT Pharma Announces First Positive DSMB Safety Review for Phase Ib CIMON Trial Testing Its Microbiome Ecosystem Therapy Capsule Formulation in AML Patients
12/22/2020
Independent Data Safety and Monitoring Board (DSMB) recommends continuing CIMON study and initiating dosing of second patient cohort
-
MaaT Pharma Presents Positive Updated Results with its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute GvHD at ASH 2020 Annual Meeting
12/7/2020
Data showed MaaT013 to be safe and effective in 29 heavily pre-treated and immunocompromised gastrointestinal (GI) acute Graft-versus-Host-Disease (aGvHD) patients
-
MaaT Pharma Announces Series B Extension and Final Closing with Total of €25 Million ($29.5 Million)
12/1/2020
Additional proceeds will be used primarily to accelerate the development of a proprietary fermentation process to design targeted, full-ecosystem, large-scale, microbiome-based products
-
MaaT Pharma to Provide Data Update for Lead Microbiome Biotherapeutic in Oral Presentation at 62nd American Society of Hematology (ASH) Annual Meeting
11/26/2020
Treatment of 29 acute gastrointestinal Graft-versus-Host-Disease patients with full-ecosystem microbiome restoration biotherapeutic MaaT013 reported safe, demonstrating positive impact
-
MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic
11/12/2020
Study will evaluate safety, dosing regimen and activity of MaaT033 in patients with acute myeloid leukemia receiving intensive chemotherapy
-
BioSpace Global Roundup, Sept. 3
9/3/2020
Biopharma and life science companies from across the globe provide updates on their pipelines and businesses. -
MaaT Pharma Announces Positive Data for Its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46th Annual Meeting of the EBMT
8/31/2020
MaaT Pharma Announces Positive Data for Its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46 th Annual Meeting of the EBMT -- Clinical data was gathered from eleven patients with gastrointestinal (GI) aGvHD treated with MaaT013, MaaT Pharma’s full-ecosystem microbiota biotherapeutic, as part of a compassionate use program -- -- MaaT013 provided positive impact with satisfactory safety profile in al
-
MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
8/28/2020
Data from the Company’s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will be highlighted in an e-poster presentation
-
MaaT Pharma Appoints Claude Bertrand, Servier’s Executive Vice President of R&D, as Independent Board Member and Welcomes New Chief Medical Officer John Weinberg
7/16/2020
MaaT Pharma announced the appointment of Claude Bertrand, PharmD, PhD, as an independent member to the company’s Board of Directors and welcomes John Weinberg, MD, as new Chief Medical Officer.
-
MaaT Pharma Appoints Savita Bernal as Chief Business Officer
5/28/2020
MaaT Pharma strengthens management team adding strategic business development and product marketing expertise